Pfizer / Allergan
Pfizer Inc. said Nov. 23 that it will combine with Irish drugmaker Allergan plc in a tax-inversion deal valued at $160 billion. The transaction was the largest announced in 2015, which was the strongest year for M&A on record, according to data compiled by Thomson Reuters.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
